Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 6/20 | 0.38 |
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820315 | 0.92 | DPP4 (0.41) | HRH3DPP4MC4RGRM5CHRM4 | |
| SCHEMBL13841885 | 0.92 | MC4R (0.43) | DPP4MC4RGRM5CHRM4PGR | |
| SCHEMBL13841910 | 0.92 | MC4R (0.43) | DPP4MC4RGRM5CHRM4PGR | |
| SCHEMBL2817641 | 0.91 | CHRM4 (0.44) | DPP4MC4RHTR1AHTR1DHTR1B | |
| SCHEMBL3638917 | 0.91 | DPP4 (0.44) | DPP4MC4RGRM5CHRM4PGR | |
| SCHEMBL2818206 | 0.91 | POLB (0.40) | DPP4MC4RHTR1AHTR1DHTR1B | |
| SCHEMBL2819553 | 0.90 | MC4R (0.43) | DPP4MC4RGRM5CHRM4PGR | |
| SCHEMBL2821462 | 0.89 | MC4R (0.41) | DPP4MC4RHTR1AHTR1DHTR1B | |
| SCHEMBL2819575 | 0.89 | MC4R (0.41) | DPP4MC4RHTR1AHTR1DHTR1B | |
| SCHEMBL2819005 | 0.88 | CHRM4 (0.43) | DPP4MC4RGRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528136-B2 | for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | SLC6A3, OPRL1, OPRK1 | HRH3 125/4885DPP4 1004/4885MC4R 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.